Mercado europeu de diagnóstico molecular, por produtos (reagentes e kits, instrumentos e serviços e software), tecnologia (espectrometria de massa (MS), eletroforese capilar, sequenciação de nova geração (NGS), chips e microarray, métodos baseados em reações em cadeia da polimerase (PCR) , Citogenética, Hibridização In Situ (ISH ou FISH), Imagiologia Molecular e Outros), Aplicação (Oncologia, Farmacogenómica, Microbiologia, Exames Pré-natais, Tipagem de Tecidos, Rastreio de Sangue, Doenças Cardiovasculares, Doenças Neurológicas, Doenças Infecciosas e Outras), Utilizador Final ( Hospital, laboratórios clínicos e académicos), país (Alemanha, França, Espanha, Turquia, Reino Unido, Países Baixos, Rússia, Suíça, Bélgica, Itália e resto da Europa) Tendências e previsões da indústria para 2028.
Análise de Mercado e Insights: Mercado Europeu de Diagnóstico Molecular
Espera-se que o mercado de diagnóstico molecular ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 5,5% no período de previsão de 2021 a 2028 e deverá atingir os 13.637,22 dólares até 2028. Espera-se que o aumento da prevalência de doenças infeciosas e cancro impulsione o crescimento do mercado de diagnóstico molecular.
O diagnóstico molecular identifica ou diagnostica doenças como doenças infeciosas , doenças genéticas, doenças cardiovasculares, doenças neurológicas e outras, estudando moléculas como o ADN, ARN, proteínas num tecido ou fluido. Diferentes tecnologias como a PCR, espectrometria de massa, sequenciação de geração, citogenética, hibridização in situ, imagem molecular e outras são utilizadas para diagnosticar diversas doenças.
Espera-se que a crescente procura de ferramentas de diagnóstico molecular para diagnosticar o COVID-19 impulsione o crescimento do mercado de diagnóstico molecular. Espera-se que o elevado custo da instrumentação atue como uma grande restrição para o crescimento do mercado de diagnóstico molecular. Espera-se que o aumento da população geriátrica atue como uma oportunidade para o crescimento do mercado de diagnóstico molecular. Espera-se que a elevada concorrência entre os participantes do mercado atue como um desafio para o crescimento do mercado de diagnóstico molecular.
O relatório de mercado de diagnóstico molecular fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado de diagnóstico molecular, contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito e dimensão do mercado de diagnóstico molecular
The molecular diagnostics market is segmented based on the products, technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of products, the molecular diagnostics market is segmented into reagents & kits, instruments and services & softwares. In 2021, the instruments segment is expected to dominate the molecular diagnostics market due to the rise in demand for advanced technology to diagnose diseases such as infectious diseases, cancer and others.
- On the basis of technology, the molecular diagnostics market is segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. In 2021, the polymerase chain reaction (PCR)-based methods segment is expected to dominate the molecular diagnostics market due to increased demand for PCR kits to diagnose COVID-19 and curb the pandemic.
- On the basis of application, the molecular diagnostics market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, tissue typing, blood screening, cardiovascular diseases, neurological diseases, infectious diseases and others. In 2021, the infectious diseases segment is expected to dominate the molecular diagnostics market due to the rise in infectious diseases such as flu, COVID-19, AIDS and others and the increased demand for highly efficient molecular diagnostics technology.
- On the basis of end user, the molecular diagnostics market is segmented into hospital, clinical laboratories and academics. In 2021, the clinical laboratories segment is expected to dominate the molecular diagnostics market due to the rising number of patients with various illnesses and the growing need for diagnostics instruments.
Europe Molecular Diagnostics Market Country Level Analysis
Europe molecular diagnostics market is analyzed and market size information is provided by the country, products, technology, application and end user as referenced above.
The countries covered in the Europe molecular diagnostics market report are the Germany, France, Spain, Turkey, U.K., Netherlands, Russia, Switzerland, Belgium, Italy and rest of Europe.
The products segment in Germany region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increase in demand for diagnosis instrument to diagnose COVID-19 patients and other cardiovascular diseases, infectious diseases and others. The products segment in Belgium is dominating the Europe molecular diagnostics market owing to increased healthcare expenditure. The U.K. is leading the growth of the Europe molecular diagnostics market for risk segment due to increasing demand for point-of-care testing and precision medicine.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to enhance the Awareness for Molecular Diagnostics is Boosting the Molecular Diagnostics Market Growth
The molecular diagnostics market also provides you with detailed market analysis for every country growth in molecular diagnostics market. Additionally, it provides the detail information regarding the molecular diagnostics market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.
Competitive Landscape and Molecular Diagnostics Market Share Analysis
The molecular diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe molecular diagnostics market.
The major companies which are dealing in the Europe molecular diagnostics market report are Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BD, bioMérieux SA, Cepheid, Hologic, Inc., Myriad Genetics, Inc., QIAGEN, Agilent Technologies, Inc., Quidel Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., IMMUCOR, Luminex Corporation, Meridian Bioscience, F Hoffmann-La Roche Ltd and GenMark Diagnostics, Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Muitos contratos, acordos e lançamentos são também iniciados pelas empresas de todo o mundo que estão também a acelerar o mercado de diagnóstico molecular.
Por exemplo,
- Em junho de 2021, a Thermo Fisher Scientific Inc. lançou um novo produto chamado Attune CytPix, um citómetro de fluxo fluorescente que oferece imagens melhoradas e foco acústico com uma câmara de alta velocidade.
A colaboração, o lançamento de produtos, a expansão do negócio, a atribuição de prémios e reconhecimento, as joint ventures e outras estratégias dos players do mercado estão a melhorar a presença da empresa no mercado de diagnóstico molecular, o que também proporciona o benefício para o crescimento do lucro da organização.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MOLECULAR DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRODUCT AND BRAND ANALYSIS: EUROPE MOLECULAR DIAGNOSTICS MARKET
4.2 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN EUROPE MOLECULAR DIAGNOSTICS MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING DEMAND FOR MOLECULAR DIAGNOSTIC TOOLS TO DIAGNOSE COVID-19
5.1.2 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER
5.1.3 RISING FUNDING FOR MOLECULAR DIAGNOSIS PRODUCTS
5.1.4 RISING DEMAND FOR POINT-OF-CARE (POC) TESTING
5.1.5 DEVELOPMENT OF COMPANION DIAGNOSTIC ASSAY AND PERSONALIZED MEDICINES
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENTATIONS
5.2.2 STRINGENT LEGAL AND REGULATORY STANDARDS ARE EXPECTED TO HAMPER THE MARKET GROWTH
5.2.3 DELAY IN APPROVAL OF EXPERIMENTAL TEST FOR MOLECULAR DIAGNOSIS
5.3 OPPORTUNITIES
5.3.1 RISING GERIATRIC POPULATION
5.3.2 INCREASING ADOPTION OF ANALYSER SOFTWARE FOR MOLECULAR DIAGNOSIS
5.3.3 RISING AWARENESS REGARDING RAPID TECHNOLOGICAL ADVANCEMENTS
5.3.4 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
1.4 CHALLENGES
5.3.5 HIGH COMPETITION AMONG MARKET PLAYERS
5.3.6 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE EUROPE MOLECULAR DIAGNOSTICS MARKET
6.1 ANALYSIS ON IMPACT OF COVID-19 ON THE EUROPE MOLECULAR DIAGNOSTICS MARKET
6.2 AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVES FOR GROWTH OF THE MOLECULAR DIAGNOSTICS MARKET
6.3 IMPACT ON DEMAND
6.4 IMPACT ON SUPPLY CHAIN
6.5 IMPACT ON PRICE
6.6 STRATEGIC INITIATIVES BY MANUFACTURERS
6.7 THE RISING COVID-19 CASES IS LEADING THE MOLECULAR DIAGNOSTICS MARKET
6.8 CONCLUSION
7 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 FULLY AUTOMATED INSTRUMENTS
7.2.2 SEMI-AUTOMATED INSTRUMENTS
7.3 REAGENTS AND KITS
7.4 SERVICES AND SOFTWARES
8 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
8.2.1 REAL-TIME PCR
8.2.2 DIGITAL PCR
8.2.3 REVERSE TRANSCRIPTASE PCR
8.2.4 QUANTITATIVE FLUORESCENT PCR
8.2.5 DIRECT LINEAR ANALYSIS
8.2.6 COLD PCR
8.3 NEXT GENERATION SEQUENCING (NGS)
8.4 CYTOGENETICS
8.5 CAPILLARY ELECTROPHORESIS
8.6 IN SITU HYBRIDIZATION (ISH OR FISH)
8.7 MOLECULAR IMAGING
8.7.1 OPTICAL IMAGING
8.7.2 FDG-PET
8.8 MASS SPECTROMETRY (MS)
8.9 CHIPS AND MICROARRAY
8.1 OTHERS
9 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 INFECTIOUS DISEASES
9.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.2.2 NEXT GENERATION SEQUENCING (NGS)
9.2.3 CYTOGENETICS
9.2.4 CAPILLARY ELECTROPHORESIS
9.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.2.6 MOLECULAR IMAGING
9.2.7 MASS SPECTROMETRY (MS)
9.2.8 CHIPS AND MICROARRAY
9.2.9 OTHERS
9.3 MICROBIOLOGY
9.3.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.3.2 NEXT GENERATION SEQUENCING (NGS)
9.3.3 CYTOGENETICS
9.3.4 CAPILLARY ELECTROPHORESIS
9.3.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.3.6 MOLECULAR IMAGING
9.3.7 MASS SPECTROMETRY (MS)
9.3.8 CHIPS AND MICROARRAY
9.3.9 OTHERS
9.4 BLOOD SCREENING
9.4.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.4.2 NEXT GENERATION SEQUENCING (NGS)
9.4.3 CYTOGENETICS
9.4.4 CAPILLARY ELECTROPHORESIS
9.4.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.4.6 MOLECULAR IMAGING
9.4.7 MASS SPECTROMETRY (MS)
9.4.8 CHIPS AND MICROARRAY
9.4.9 OTHERS
9.5 ONCOLOGY
9.5.1 ONCOLOGY, BY CANCER TYPE
9.5.1.1 BREAST CANCER
9.5.1.2 COLORECTAL CANCER
9.5.1.3 LUNG CANCER
9.5.1.4 PROSTATE CANCER
9.5.1.5 OTHERS
9.5.2 ONCOLOGY, BY TECHNOLOGY
9.5.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.5.2.2 NEXT GENERATION SEQUENCING (NGS)
9.5.2.3 CYTOGENETICS
9.5.2.4 CAPILLARY ELECTROPHORESIS
9.5.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.5.2.6 MOLECULAR IMAGING
9.5.2.7 MASS SPECTROMETRY (MS)
9.5.2.8 CHIPS AND MICROARRAY
9.5.2.9 OTHERS
9.6 TISSUE TYPING
9.6.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.6.2 NEXT GENERATION SEQUENCING (NGS)
9.6.3 CYTOGENETICS
9.6.4 CAPILLARY ELECTROPHORESIS
9.6.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.6.6 MOLECULAR IMAGING
9.6.7 MASS SPECTROMETRY (MS)
9.6.8 CHIPS AND MICROARRAY
9.6.9 OTHERS
9.7 PHARMACOGENOMICS
9.7.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.7.2 NEXT GENERATION SEQUENCING (NGS)
9.7.3 CYTOGENETICS
9.7.4 CAPILLARY ELECTROPHORESIS
9.7.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.7.6 MOLECULAR IMAGING
9.7.7 MASS SPECTROMETRY (MS)
9.7.8 CHIPS AND MICROARRAY
9.7.9 OTHERS
9.8 PRENATAL TESTS
9.8.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.8.2 NEXT GENERATION SEQUENCING (NGS)
9.8.3 CYTOGENETICS
9.8.4 CAPILLARY ELECTROPHORESIS
9.8.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.8.6 MOLECULAR IMAGING
9.8.7 MASS SPECTROMETRY (MS)
9.8.8 CHIPS AND MICROARRAY
9.8.9 OTHERS
9.9 NEUROLOGICAL DISEASES
9.9.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.9.2 NEXT GENERATION SEQUENCING (NGS)
9.9.3 CYTOGENETICS
9.9.4 CAPILLARY ELECTROPHORESIS
9.9.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.9.6 MOLECULAR IMAGING
9.9.7 MASS SPECTROMETRY (MS)
9.9.8 CHIPS AND MICROARRAY
9.9.9 OTHERS
9.1 CARDIOVASCULAR DISEASES
9.10.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.10.2 NEXT GENERATION SEQUENCING (NGS)
9.10.3 CYTOGENETICS
9.10.4 CAPILLARY ELECTROPHORESIS
9.10.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.10.6 MOLECULAR IMAGING
9.10.7 MASS SPECTROMETRY (MS)
9.10.8 CHIPS AND MICROARRAY
9.10.9 OTHERS
9.11 OTHERS
9.11.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.11.2 NEXT GENERATION SEQUENCING (NGS)
9.11.3 CYTOGENETICS
9.11.4 CAPILLARY ELECTROPHORESIS
9.11.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.11.6 MOLECULAR IMAGING
9.11.7 MASS SPECTROMETRY (MS)
9.11.8 CHIPS AND MICROARRAY
9.11.9 OTHERS
10 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
11 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 ITALY
11.1.4 RUSSIA
11.1.5 U.K.
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 SWITZERLAND
11.1.9 BELGIUM
11.1.10 NETHERLANDS
11.1.11 REST OF EUROPE
12 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT
14 COMPANY PROFILES
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 ILLUMINA, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 HOLOGIC, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BIOMÉRIEUX SA
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 REVENUE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BD
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 BECKMAN COULTER, INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BIO-RAD LABORATORIES, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENTS
14.1 CEPHEID
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 GENMARK DIAGNOSTICS, INC.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 IMMUCOR
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 LIFE TECHNOLOGIES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 LUMINEX CORPORATION
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 MERRIDIAN BIOSCIENCE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 MYRIAD GENETICS, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 QIAGEN
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 QUIDEL CORPORATION
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 SIEMENS HEALTHCARE GMBH
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 2 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 EUROPE REAGENTS AND KITS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE SERVICES AND SOFTWARES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE CYTOGENETICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE CAPILLARY ELECTROPHORESIS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE INS SITU HYBRIDIZATION (ISH OR FISH) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 15 EUROPE MASS SPECTROMETRY (MS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE CHIPS AND MICROARRAY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 21 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 23 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 25 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 27 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 EUROPE CLINICAL LABORATORIES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE HOSPITAL IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 EUROPE ACADEMICS IN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 44 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 45 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 47 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 48 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 49 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 50 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 51 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 GERMANY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 65 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 66 GERMANY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 67 GERMANY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 68 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 GERMANY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 70 GERMANY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 GERMANY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 74 GERMANY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 GERMANY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 GERMANY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 77 GERMANY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 78 GERMANY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 79 GERMANY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 80 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 82 FRANCE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 83 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 84 FRANCE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 85 FRANCE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 87 FRANCE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 88 FRANCE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 89 FRANCE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 FRANCE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 FRANCE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 92 FRANCE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 93 FRANCE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 94 FRANCE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 FRANCE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 96 FRANCE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 97 FRANCE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 98 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 ITALY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 100 ITALY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 102 ITALY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 103 ITALY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 104 ITALY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 ITALY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 106 ITALY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 107 ITALY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 108 ITALY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 109 ITALY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 110 ITALY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 111 ITALY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 ITALY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 ITALY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 114 ITALY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 115 ITALY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 116 ITALY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 117 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 118 RUSSIA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 119 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 120 RUSSIA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 121 RUSSIA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 122 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 RUSSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 RUSSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 125 RUSSIA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 126 RUSSIA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 127 RUSSIA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 128 RUSSIA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 129 RUSSIA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 130 RUSSIA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 131 RUSSIA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 132 RUSSIA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 RUSSIA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 134 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 135 U.K. MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 136 U.K. INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 137 U.K. MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 138 U.K. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 139 U.K. MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 140 U.K. MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 141 U.K. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 142 U.K. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 U.K. PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 144 U.K. MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 U.K. PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 U.K. TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 147 U.K. BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 148 U.K. CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 149 U.K. NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 U.K. INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 U.K. OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 152 U.K. MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 154 SPAIN INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 156 SPAIN POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 157 SPAIN MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 158 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 159 SPAIN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 160 SPAIN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 161 SPAIN PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 162 SPAIN MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 163 SPAIN PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 164 SPAIN TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 165 SPAIN BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 166 SPAIN CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 167 SPAIN NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 168 SPAIN INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 169 SPAIN OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 170 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 171 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 172 TURKEY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 173 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 174 TURKEY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 175 TURKEY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 176 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 177 TURKEY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 178 TURKEY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 179 TURKEY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 TURKEY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 181 TURKEY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 182 TURKEY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 TURKEY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 184 TURKEY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 185 TURKEY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 186 TURKEY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 187 TURKEY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 188 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 189 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 190 SWITZERLAND INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 191 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 192 SWITZERLAND POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 193 SWITZERLAND MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 194 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 195 SWITZERLAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 196 SWITZERLAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 197 SWITZERLAND PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 198 SWITZERLAND MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 199 SWITZERLAND PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 200 SWITZERLAND TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 201 SWITZERLAND BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 202 SWITZERLAND CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 203 SWITZERLAND NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 204 SWITZERLAND INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 205 SWITZERLAND OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 206 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 207 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 208 BELGIUM INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 209 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 210 BELGIUM POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 211 BELGIUM MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 212 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 213 BELGIUM ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 214 BELGIUM ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 215 BELGIUM PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 216 BELGIUM MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 217 BELGIUM PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 218 BELGIUM TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 219 BELGIUM BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 220 BELGIUM CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 221 BELGIUM NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 222 BELGIUM INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 223 BELGIUM OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 224 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 225 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 226 NETHERLANDS INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 227 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 228 NETHERLANDS POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 229 NETHERLANDS MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 230 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 231 NETHERLANDS ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 232 NETHERLANDS ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 233 NETHERLANDS PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 234 NETHERLANDS MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 235 NETHERLANDS PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 236 NETHERLANDS TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 237 NETHERLANDS BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 238 NETHERLANDS CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 239 NETHERLANDS NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 240 NETHERLANDS INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 241 NETHERLANDS OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 242 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 243 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 EUROPE MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE MOLECULAR DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE MOLECULAR DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE MOLECULAR DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MOLECULAR DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MOLECULAR DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE MOLECULAR DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE MOLECULAR DIAGNOSTICS MARKET AND GROWING WITH THE HIGHEST SHARE IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO DRIVE THE EUROPE MOLECULAR DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MOLECULAR DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE MOLECULAR DIAGNOSTICS MARKET
FIGURE 14 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020
FIGURE 16 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020
FIGURE 17 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 18 EUROPE MOLECULAR DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 19 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 20 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 21 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 22 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY PRODUCT (2021 & 2028)
FIGURE 23 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
